NCT04657666 - Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

May 4, 2022

Study Completion Date

May 10, 2022

Conditions

Spasticity in Participants With Multiple Sclerosis

Interventions

DRUG

Nabiximols

oromucosal spray

DRUG

Placebo

oromucosal spray

Trial Locations (16)

565 01

Clinical Trial Site, Choceň

61-853

Clinical Trial Site 2, Poznan

62-064

Clinical Trial Site 1, Poznan

85-163

Clinical Trial Site, Bydgoszcz

30-539

Clinical Trial Site 1, Krakow

32-600

Clinical Trial Site, Oświęcim

01-211

Clinical Trial Site 2, Warsaw

01-868

Clinical Trial Site 1, Warsaw

80-803

Clinical Trial Site, Gdansk

41-500

Clinical Trial Site, Chorzów

40-123

Clinical Trial Site 3, Katowice

40-571

Clinical Trial Site 1, Katowice

40-684

Clinical Trial Site 2, Katowice

30-149

Clinical Trial Site, Krakow

41-800

Clinical Trial Site, Zabrze

25-726

Clinical Trial Site, Kielce